Related Experiment Video

Updated: Dec 10, 2025

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

9.4K

An Antibody Attack against Body Wasting in Cancer

Maria Rohm1, Stephan Herzig2

  • 1Institute for Diabetes and Cancer (IDC), Helmholtz Munich, Neuherberg, Germany; Joint Heidelberg-IDC Transnational Diabetes Program, Heidelberg University Hospital, Heidelberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany.

Cell Metabolism
|September 3, 2020
PubMed

Insights

Researchers developed an antibody targeting the GDF15-GFRAL pathway to combat cancer cachexia, a severe wasting condition. This novel approach successfully prevented tumor-induced body wasting in animal models, offering new therapeutic potential.

Area of Science:

  • Oncology
  • Molecular Biology
  • Translational Medicine

Background:

  • Cancer cachexia is a debilitating, incurable condition characterized by significant muscle and fat loss in cancer patients.
  • The molecular mechanisms driving cachexia pathogenesis remain incompletely understood, hindering effective prevention strategies.
  • The Growth Differentiation Factor 15 (GDF15) and its receptor Glial cell-derived neurotrophic factor receptor alpha-like (GFRAL) axis has been implicated in cachexia.

Purpose of the Study:

  • To develop and characterize an antagonistic antibody targeting the GDF15-GFRAL axis.
  • To evaluate the efficacy of this antibody in blocking tumor-induced body wasting in preclinical models.

Main Methods:

  • Development of a novel antibody designed to inhibit the interaction between GDF15 and GFRAL.
  • Characterization of the antibody's binding affinity and inhibitory function.
  • Assessment of the antibody's effect on body weight and composition in experimental animal models of cancer cachexia.

Main Results:

  • The developed antibody effectively antagonizes the GDF15-GFRAL signaling pathway.
  • Administration of the antibody significantly blocked tumor-induced wasting of muscle and fat tissue in experimental animals.
  • The antibody demonstrated robust efficacy in preventing cachexia progression in vivo.

Conclusions:

  • The GDF15-GFRAL axis is a critical mediator of cancer cachexia.
  • An antagonistic antibody targeting this axis represents a promising therapeutic strategy for preventing cancer-induced body wasting.
  • Further investigation into this antibody could lead to novel treatments for cancer cachexia patients.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.7K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.5K
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
979
Antibody Actions01:26

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
2.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.7K